As observed in clinical disease, baricitinib treatment improves the clinical manifestations and inflammatory and IFN biomarkers in patients with the monogenic interferonopathies CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), SAVI (STING-associated vasculopathy with onset in infancy), and other interferonopathies [138]. Here, STING1 is linked to vascular disorder.